C4 Therapeutics, Inc. Deferred Revenue
C4 Therapeutics, Inc. (CCCC) had Deferred Revenue of $50.29 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2022-05-05
- 2022-03-31: Deferred Revenue $50.29M.
- 2021-12-31: Deferred Revenue $56.17M.
- 2021-09-30: Deferred Revenue $71.23M.
- 2021-06-30: Deferred Revenue $74.88M.
| Period end | Deferred Revenue |
|---|---|
| 2022-03-31 | $50.29M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $56.17M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $71.23M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $74.88M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $77.45M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $81.22M 10-K · filed 2022-02-24 |
| 2020-09-30 | $85.00M 10-Q · filed 2020-11-12 |
| 2019-12-31 | $93.42M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |